EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety and effectiveness of budesonide rectal foam for ulcerative colitis in a large-scale, multicenter, prospective observational study: final report of post-marketing surveillance in Japan

Masayuki Saruta, Teppei Omori, Akira Nagaki, Yuki Arai, Minami Umeyama, Shinsuke Kurosu, Kiyotoshi Kuramoto, Yasuo Suzuki

Intestinal Research · 31.10.2026 · 24 (4) · 744-756

DOI: 10.5217/ir.2025.00164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intestinal Research, erschienen am 31.10.2026. Verfasst von Masayuki Saruta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. m.saruta@jikei.a…. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: EA Pharma Co., Ltd., Kissei Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Budesonide rectal foam was approved in Japan in 2017 for mild to moderate active ulcerative colitis (UC). This is the final report of post-marketing surveillance to evaluate real-world safety and effectiveness.

Methods

This Japanese large-scale, prospective, multicenter, open-label observational study included patients with active-phase mild to moderate UC newly started on budesonide 2 mg rectal foam. Safety was evaluated by adverse drug reactions (ADRs). Effectiveness was evaluated using clinical remission rates and partial Mayo scores. Effectiveness by background (disease phenotype, severity, clinical course, age, prior topical therapy, baseline advanced therapy [biologicals/Janus kinase inhibitors]) was also assessed.

Results

There were 633 and 503 patients in the safety and effectiveness analyses, respectively. ADRs occurred in 4.3% (27/633) of patients. Eight glucocorticoid-related ADRs occurred in 7 patients (1.1%). Clinical remission rates were 44.2% (165/373), 72.1% (191/265), and 69.8% (333/477) at week 2, week 6, and the final evaluation, respectively. There were statistically significant changes from baseline in partial Mayo scores at all timepoints (all P< 0.0001 vs. baseline). At 2, 4, 6, and 6–12 weeks, mean± standard deviation changes from baseline in partial Mayo scores were −2.1 ± 1.9, −2.7 ± 2.1, −3.1 ± 2.3, and −3.4 ± 2.3 points, respectively. Statistically significant improvements were maintained at all timepoints in subgroup analyses by background (disease phenotype, severity, clinical course, age, prior topical therapy, baseline advanced therapy).

Conclusions

No new safety concerns were identified. Partial Mayo score improved in a variety of patient background factors. Health condition improvements were confirmed in this Japanese post-marketing surveillance. (Japan Registry of Clinical Trials, identifier jRCT1080223802)

Schlagwörter

Stichwörter der Autor:innen

BudesonideSurveillanceTherapeuticsUlcerative colitis

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. m.saruta@jikei.ac.jp.
  • Department of Gastroenterology and Hepatology, Kyorin University Suginami Hospital, Kyorin University School of Medicine, Tokyo, Japan.
  • EA Pharma Co., Ltd., Tokyo, Japan; 4Kissei Pharmaceutical Co., Ltd., Tokyo, Japan; 5Ginza Central Clinic, Tokyo, Japan.
  • Kissei Pharmaceutical Co., Ltd., Tokyo, Japan.
  • Ginza Central Clinic, Tokyo, Japan.

Förderung

  • EA Pharma Co., Ltd.
  • Kissei Pharmaceutical Co., Ltd.

Zitieren

APA

Saruta, M., Omori, T., Nagaki, A., Arai, Y., Umeyama, M., Kurosu, S., Kuramoto, K., & Suzuki, Y. (2026). Safety and effectiveness of budesonide rectal foam for ulcerative colitis in a large-scale, multicenter, prospective observational study: final report of post-marketing surveillance in Japan. Intestinal Research, 24(4), 744-756. https://doi.org/10.5217/ir.2025.00164

Vancouver

Saruta M, Omori T, Nagaki A, Arai Y, Umeyama M, Kurosu S, et al. Safety and effectiveness of budesonide rectal foam for ulcerative colitis in a large-scale, multicenter, prospective observational study: final report of post-marketing surveillance in Japan. Intestinal Research. 2026;24(4):744-756. doi:10.5217/ir.2025.00164

BibTeX
@article{Saruta2026,
  author = {Saruta, Masayuki and Omori, Teppei and Nagaki, Akira and Arai, Yuki and Umeyama, Minami and Kurosu, Shinsuke and Kuramoto, Kiyotoshi and Suzuki, Yasuo},
  title = {Safety and effectiveness of budesonide rectal foam for ulcerative colitis in a large-scale, multicenter, prospective observational study: final report of post-marketing surveillance in Japan},
  journal = {Intestinal Research},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {744--756},
  doi = {10.5217/ir.2025.00164}
}
Kostenlos starten →